YTX-7739, a potential disease-modifying therapy for Parkinson’s disease, was safe, well-tolerated, and found to have a favorable pharmacological profile when given to a group of healthy volunteers. Yumanity Therapeutics provided those early findings from a recently completed single ascending-dose (SAD) Phase 1 clinical trial. Based on the results, Yumanity will continue to explore YTX-7739’s safety and tolerability in healthy volunteers in its multiple ascending-dose (MAD) Phase 1 study. With participant enrollment now complete, Yumanity anticipates announcing data from the…

You must be logged in to read/download the full post.